S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

Advanz Pharma Stock Price, Forecast & Analysis (OTCMKTS:CXRXF)

$11.28
+1.06 (+10.37 %)
(As of 11/12/2019)
Today's Range
$11.28
Now: $11.28
$11.29
50-Day Range
$9.85
MA: $11.78
$13.77
52-Week Range
$9.32
Now: $11.28
$19.90
Volume215 shs
Average Volume276 shs
Market Capitalization$551.70 million
P/E Ratio0.96
Dividend YieldN/A
Beta0.57
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CXRXF
CUSIPN/A
CIKN/A
Phone905-842-5150

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$536.99 million
Cash Flow$8.95 per share
Book Value$4.02 per share

Profitability

Net Income$1.47 billion

Miscellaneous

Employees435
Market Cap$551.70 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive CXRXF News and Ratings via Email

Sign-up to receive the latest news and ratings for CXRXF and its competitors with MarketBeat's FREE daily newsletter.


Advanz Pharma (OTCMKTS:CXRXF) Frequently Asked Questions

What is Advanz Pharma's stock symbol?

Advanz Pharma trades on the OTCMKTS under the ticker symbol "CXRXF."

How were Advanz Pharma's earnings last quarter?

Advanz Pharma Corp (OTCMKTS:CXRXF) issued its earnings results on Thursday, November, 7th. The company reported ($0.22) earnings per share (EPS) for the quarter. The business had revenue of $119.64 million for the quarter. Advanz Pharma had a negative net margin of 50.87% and a negative return on equity of 68.51%. View Advanz Pharma's Earnings History.

When is Advanz Pharma's next earnings date?

Advanz Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Advanz Pharma.

What is the consensus analysts' recommendation for Advanz Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanz Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advanz Pharma.

Has Advanz Pharma been receiving favorable news coverage?

Headlines about CXRXF stock have trended very negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Advanz Pharma earned a news impact score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Advanz Pharma.

Who are some of Advanz Pharma's key competitors?

What other stocks do shareholders of Advanz Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanz Pharma investors own include Boston Beer (SAM), ANI Pharmaceuticals (ANIP), Broadcom (AVGO), Boxlight (BOXL), Comcast (CMCSA), Corbus Pharmaceuticals (CRBP), Cognizant Technology Solutions (CTSH), CyberOptics (CYBE), Dollar Tree (DLTR) and Educational Development (EDUC).

Who are Advanz Pharma's key executives?

Advanz Pharma's management team includes the folowing people:
  • Mr. Graeme Neville Duncan, CEO & Director (Age 45)
  • Mr. Karl Ian Belk, Chief Operations Officer (Age 51)
  • Mr. Adeel Ahmad, Chief Financial Officer (Age 45)
  • Mr. Robert Sully, Gen. Counsel (Age 46)
  • Mr. Paul Burden, Pres of U.K. & Ireland and Corp. Communications (Age 44)

How do I buy shares of Advanz Pharma?

Shares of CXRXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Advanz Pharma's stock price today?

One share of CXRXF stock can currently be purchased for approximately $11.28.

How big of a company is Advanz Pharma?

Advanz Pharma has a market capitalization of $551.70 million and generates $536.99 million in revenue each year. The company earns $1.47 billion in net income (profit) each year or $11.78 on an earnings per share basis. Advanz Pharma employs 435 workers across the globe.View Additional Information About Advanz Pharma.

What is Advanz Pharma's official website?

The official website for Advanz Pharma is http://www.advanzpharma.com/.

How can I contact Advanz Pharma?

Advanz Pharma's mailing address is 5770 HURONTARIO STREET SUITE 310, MISSISSAUGA A6, L5R 3GB. The company can be reached via phone at 905-842-5150 or via email at [email protected]


MarketBeat Community Rating for Advanz Pharma (OTCMKTS CXRXF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about Advanz Pharma and other stocks. Vote "Outperform" if you believe CXRXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CXRXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel